Race Oncology Limited (RAC.AX) Stock Analysis & Winston Score

Race Oncology is an Australian biotechnology company focused on developing cancer treatments. Its lead drug candidate is bisantrene, an older chemotherapy compound that the company is working to repurpose for treating blood cancers such as acute myeloid leukemia (AML). The company's main customers would be cancer patients and hospitals, though it has not yet brought a product to market. Race Oncology earns no meaningful revenue from product sales yet. It is a clinical-stage company, meaning it funds its operations through capital raises while spending money on research and clinical trials. The company is based in Australia and operates at a significant loss, as reflected in its deeply negative operating margin. The key question for investors is whether bisantrene can successfully complete clinical trials and gain regulatory approval, which would be the primary growth driver — but failure at any stage of trials remains the central risk for a company with no approved products and no commercial revenue.